European life sciences investor Medicxi has bundled together six privately-held companies with dermatology medicines in development under a single drugmaker – called Alys
Anglo-Swiss life sciences investment company Medicxi has raised $400 million for its fourth fund, which will focus on supporting 'asset-centric' companies at all stages of
Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment.
GlaxoSmithKline has fired its former research boss Moncef Slaoui from the board of Galvani Bioelectronics, a company it majority owns, after an internal investigation found he sexually hara
Putting together a quarter-billion dollar pharma company from ten mergers in four months is not for the faint-hearted – but that’s what biotech investment guru Francesco de Rubertis has ach
New $300m fund aimed at helping European biotechs to grow, providing alternative to an IPO or 'generally suboptimal' licensing or big pharma acquisition